These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27655129)

  • 21. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
    Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.
    Drube S; Weber F; Göpfert C; Loschinski R; Rothe M; Boelke F; Diamanti MA; Löhn T; Ruth J; Schütz D; Häfner N; Greten FR; Stumm R; Hartmann K; Krämer OH; Dudeck A; Kamradt T
    Oncotarget; 2015 Oct; 6(30):28833-50. PubMed ID: 26353931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
    Moon JH; Hong SW; Kim JE; Shin JS; Kim JS; Jung SA; Ha SH; Lee S; Kim J; Lee DH; Park YS; Kim DM; Park SS; Hong JK; Kim DY; Kim EH; Jung J; Kim MJ; Kim SM; Deming DA; Kim K; Kim TW; Jin DH
    Br J Cancer; 2019 Apr; 120(9):941-951. PubMed ID: 30944457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in
    Inoue A; Mizushima T; Wu X; Okuzaki D; Kambara N; Ishikawa S; Wang J; Qian Y; Hirose H; Yokoyama Y; Ikeshima R; Hiraki M; Miyoshi N; Takahashi H; Haraguchi N; Hata T; Matsuda C; Doki Y; Mori M; Yamamoto H
    Mol Cancer Ther; 2018 May; 17(5):977-987. PubMed ID: 29545333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
    Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
    Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
    Lin Q; Lai R; Chirieac LR; Li C; Thomazy VA; Grammatikakis I; Rassidakis GZ; Zhang W; Fujio Y; Kunisada K; Hamilton SR; Amin HM
    Am J Pathol; 2005 Oct; 167(4):969-80. PubMed ID: 16192633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death.
    Augeri DJ; Langenfeld E; Castle M; Gilleran JA; Langenfeld J
    Mol Cancer; 2016 Apr; 15():27. PubMed ID: 27048361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
    Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
    Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
    Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
    Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
    Yen I; Shanahan F; Merchant M; Orr C; Hunsaker T; Durk M; La H; Zhang X; Martin SE; Lin E; Chan J; Yu Y; Amin D; Neve RM; Gustafson A; Venkatanarayan A; Foster SA; Rudolph J; Klijn C; Malek S
    Cancer Cell; 2018 Oct; 34(4):611-625.e7. PubMed ID: 30300582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
    Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
    Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK Inhibition Remodels the Immune Landscape of Mutant
    Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
    Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Grifolin, neogrifolin and confluentin from the terricolous polypore Albatrellus flettii suppress KRAS expression in human colon cancer cells.
    Yaqoob A; Li WM; Liu V; Wang C; Mackedenski S; Tackaberry LE; Massicotte HB; Egger KN; Reimer K; Lee CH
    PLoS One; 2020; 15(5):e0231948. PubMed ID: 32369483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.